MEI Pharma Inc expected to post a loss of 14 cents a share - Earnings Preview

Lite Strategy

04/11/2022 11:38

* MEI Pharma Inc  MEIP.OQ   MEIP.O  is expected to show a
fall in
quarterly revenue when it reports  results on November 8
(estimated). 
    * The San Diego California-based  company is expected to
report  a
55.9% decrease in revenue to $5.897 million from $13.39 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for MEI Pharma Inc is
for a
loss of 14 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for MEI Pharma
Inc is
$4​, above​ its last closing price of $0.34. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.18       -0.19      -0.12     Beat    35.4
 Mar. 31 2022  -0.18       -0.18      -0.07     Beat    61.6
 Dec. 31 2021  -0.20       -0.20      -0.05     Beat    75.3​
 Sep. 30 2021  -0.12       -0.13      -0.11     Beat    12.7
 ​​Jun.        -0.18       -0.17      -0.05     Beat    71.4
 30 2021                                                
 Mar. 31 2021  -0.17       -0.16      -0.28     Missed  -72.3​
 Dec. 31 2020  -0.14       -0.13      -0.10     Beat    24.7
 Sep. 30 2020  -0.07       -0.08      -0.02     Beat    75.6
 This summary was machine generated November 4 at 11:38 GMT.  All
figures in US dollars  unless otherwise stated